The phenanthrene derivative PJ34 exclusively eradicates human pancreatic cancer cells in xenografts

Leonid Visochek; Dikla Atias; Itay Spektor; Asher Castiel; Talia Golan; Malka Cohen-Armon

doi:10.18632/oncotarget.27268

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

This article has been corrected. Correction in: Oncotarget. 2020; 11:571-572.

The phenanthrene derivative PJ34 exclusively eradicates human pancreatic cancer cells in xenografts

Leonid Visochek, Dikla Atias, Itay Spektor, Asher Castiel, Talia Golan and Malka Cohen-Armon _

Oncotarget. 2019; 10:6269-6282. https://doi.org/10.18632/oncotarget.27268

Metrics: PDF 4122 views | Full Text 20382 views | ?

Abstract

Leonid Visochek1, Dikla Atias3, Itay Spektor3, Asher Castiel3, Talia Golan1^,3 and Malka Cohen-Armon1^,2

1 Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 69978, Israel

2 Sagol School of Neuroscience, Tel-Aviv University, Tel-Aviv 69978, Israel

3 Oncology Institute, Sheba Medical Center, Ramat Gan 53621, Israel

Correspondence to:

Malka Cohen-Armon,

email:

[email protected]

Keywords: PJ34; pancreas cancer; stroma; PANC1 cancer xenografts

Received: May 21, 2019 Accepted: September 10, 2019 Published: October 22, 2019

ABSTRACT

Recent reports demonstrate an exclusive eradication of a variety of human cancer cells by the modified phenanthridine PJ34. Their eradication during mitosis is attributed to PJ34 preventing NuMA clustering in the mitotic spindle poles of human malignant cells, which is crucial for their normal mitosis. Here, the effect of PJ34 is tested in cell cultures and xenografts of human pancreas ductal adenocarcinoma. Evidence is presented for a substantial reduction (80–90%) of PANC1 cancer cells in xenografts, measured 30 days after the treatment with PJ34 has been terminated. Benign cells infiltrated into the PANC1 tumors (stroma) were not affected. Growth, weight gain and behavior of the treated nude mice were not impaired during, and 30 days after the treatment with PJ34. The efficient eradication of malignant cells in human pancreas cancer xenografts presents a new model of pancreas cancer treatment.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27268

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

The phenanthrene derivative PJ34 exclusively eradicates human pancreatic cancer cells in xenografts

Abstract